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Abstract
Background: Retreatments are sometimes necessary to correct residual or induced refractive errors following
refractive surgery. Many different combinations of primary treatment methods and retreatment techniques
have been studied, however, few studies have investigated wavefront-optimized (WFO) technology for retreatment
following primary refractive surgery. This study aimed to report the outcomes of WFO photorefractive keratectomy
(PRK) retreatments of refractive error following previous laser refractive surgery with PRK, laser in situ keratomileusis
(LASIK), or laser-assisted subepithelial keratectomy (LASEK).
Methods: We reviewed records of patients who underwent WFO PRK retreatments using the Allegretto Wave Eye-Q
400 Hz Excimer Laser System (Alcon Surgical) between January 2008 and April 2011 at Walter Reed Army Medical
Center and Madigan Army Medical Center. Outcomes were recorded in terms of uncorrected distance visual acuity
(UDVA), manifest refraction spherical equivalent (MRSE), corrected distance visual acuity (CDVA), and complications at
1 month (M), 3 M, and 6 M post-op.
Results: Seventy-eight patients (120 eyes) underwent WFO PRK retreatment during the study period. Primary surgery
was surface ablation in 87 eyes (78 PRK, 9 LASEK) and LASIK in 33 eyes. The mean spherical equivalent before
retreatment was −0.79 ± 0.94 D (−3.00 to 1.88 D). UDVA was≥ 20/20 in 69 eyes (60.0 %) at 1 M, 54 eyes (71.1 %) at 3 M,
and 27 eyes (73.0 %) at 6 M follow-up. MRSE was within ±0.50 D of emmetropia in 78 eyes (67.8 %) at 1 M, 59 eyes
(77.6 %) at 3 M, and 25 eyes (67.6 %) at 6 M follow-up. CDVA was maintained within ±1 line of pre-op in 113 of 115
eyes (98.3 %) at 1 M, 74 of 76 eyes (97.4 %) at 3 M, and 37 eyes (100 %) at 6 M follow-up.
Conclusion: Although follow-up was limited beyond 3 M, WFO PRK retreatments in patients with residual refractive
error may be a safe and effective procedure. Further studies are necessary to determine the long-term safety
and stability of outcomes.
Keywords: Wavefront-optimized, PRK, LASIK, LASEK, Retreatment, Enhancement
* Correspondence: kevin.m.broderick2.mil@mail.mil
Meeting presentation: Portions of this material were presented at the 2011
Refractive Surgery Subspecialty Day Meeting of the International Society of
Refractive Surgery (ISRS) October 21–22, 2011 in Orlando, FL, USA (Abstract #:
RP101345). The material has not otherwise been presented or published.
Kevin M. Broderick first author and Kraig S. Bower senior author.
1Ophthalmology Service, Walter Reed National Military Medical Center, 8901
Wisconsin Avenue, Bethesda, MD 20814, USA
Full list of author information is available at the end of the article
© 2016 Broderick et al. Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Broderick et al. Eye and Vision  (2016) 3:3 
DOI 10.1186/s40662-016-0034-x
Background
Laser refractive surgery is one of the most commonly
performed eye surgeries worldwide and has been estab-
lished to be successful in correcting refractive errors.
With conventional refractive surgery, a patient may not
achieve his or her maximal visual quality potential post-
operatively as a result of changes in corneal shape and
subsequent induction of ocular aberrations [1]. Several
studies have shown that conventional methods result in
the induction of higher order aberrations, including
spherical aberration and coma, which can lead to nega-
tive visual outcomes [2, 3]. The advent of wavefront
technology has greatly improved our understanding of
ocular aberration, and with its incorporation into re-
fractive surgery techniques, patients are experiencing
better visual outcomes and greater satisfaction when
compared with conventional methods [1, 4, 5]. Even
with these improved outcomes, however, retreatments
are sometimes necessary to correct residual or induced
refractive error following refractive surgery.
Retreatment following refractive surgery is a subject
that has been extensively studied and has been observed
in many different combinations of primary treatment
methods and retreatment methods. The overall rate for
retreatment varies widely in the literature with the aver-
age rate ranging from 5.5 % to 8.3 % for primary myopic
laser in situ keratomileusis (LASIK) [5]. Prior to the
advent of wavefront technology, flap-lift retreatments
following conventional LASIK was shown to be safe and
effective in multiple studies [6–9]. Jin and Merkley [10]
illustrated that retreatment using conventional LASIK is
safe, effective, and predictable following wavefront-
guided (WFG) and standard myopic LASIK. They also
compared conventional to WFG retreatments following
primary conventional LASIK treatments in another
study [11]. Kanellopoulous and Lawrence [12], along
with several other groups, illustrated similar findings
following WFG retreatments of primary conventional
LASIK. Kashani et al. [5] observed that WFG retreat-
ments following primary WFG surgeries in both
myopes and hyperopes had favorable outcomes with
respect to safety, predictability, and efficacy. Few
studies, however, have reported outcomes specifically
of wavefront-optimized (WFO) retreatments following
refractive surgery.
To our knowledge, the only recent study addressing
retreatment data using WFO technology was a study by
Randleman et al. [13], which looked primarily at retreat-
ment rates after WFO ablation and examined potential
risk factors for retreatment, including age, sex, corneal
characteristics, and environmental factors. All patients
involved in that study underwent either WFO photore-
fractive keratectomy (PRK) or LASIK for both their pri-
mary and retreatment surgeries. In this study, we report
the visual outcomes of WFO PRK retreatment following
PRK, LASIK, and laser-assisted subepithelial keratec-
tomy (LASEK).
Methods
We performed a retrospective database review of
patients who underwent WFO PRK retreatments for re-
sidual refractive error following previous laser refractive
surgery at either the Walter Reed Army Medical Center
(WRAMC) Center for Refractive Surgery (CRS) or the
Madigan Army Medical Center (MAMC) Refractive
Surgery Center (RSC) between January 2008 and April
2011. As part of the U.S. Army Warfighter Refractive
Eye Surgery Program (WRESP), each refractive center
maintains separate outcomes databases as computerized
spreadsheets (Microsoft Excel, Redmond, Washington) to
track patient outcomes and follow-up. In addition to pa-
tient demographic information, these databases list pre-
operative refractive error, primary treatment performed,
type of retreatment performed, if any, outcomes, and any
complications. Data from patients identified as having
undergone WFO PRK retreatments were extracted from
these databases and compiled in a new computerized
spreadsheet for analysis. Prior to review of these data-
bases, approval for the study was obtained from the
institutional review board (Department of Clinical In-
vestigation) at both WRAMC and MAMC.
All patients were active duty personnel participating
in the WRESP who gave informed consent to undergo
the retreatment procedure for residual refractive error.
WRESP patients are typically 20 to 50 years old and
predominantly (74.4 %) male. All active duty soldiers
with at least 18 months of service obligation remaining
at the time of surgery are potentially eligible for partici-
pation in the program, with preference given to combat
arms soldiers [14]. Pre-operative evaluation of refractive
candidates included uncorrected distance visual acuity
(UDVA), corrected distance visual acuity (CDVA),
manifest and cycloplegic refractions, keratometry and
ultrasound corneal pachymetry, contact tonometry, and
comprehensive ophthalmic exam. Patients with active
ophthalmic disease, keratoconus, glaucoma, ocular
herpes simplex or herpes zoster, significant corneal neo-
vascularization, clinically significant lens opacity, medical
conditions that may impair healing (e.g. collagen vascular
disease, autoimmune disease, immunodeficiency disease),
lack of refractive stability within 6 months prior to sur-
gery, suspicious corneal topography, and pregnancy were
excluded from treatment. There were no set criteria in de-
termining the need for a retreatment procedure; this was
generally decided by the patient and physician.
Overall, reasons for residual refractive error following
initial laser refractive treatment include initial undertreat-
ment, overtreatment, or regression. During evaluation for
Broderick et al. Eye and Vision  (2016) 3:3 Page 2 of 7
retreatment, each patient obtained corneal tomography to
assess for and rule out evidence of ectasia or forme-fruste
keratoconus. If concerning corneal tomography was
present, the patient was no longer considered a candidate
for refractive surgery. No patients included in the study
showed evidence (either pre or post-operatively) of
corneal ectasia during the study period.
All retreatments were WFO ablations with Allegretto
Wave Eye-Q 400 Hz Excimer Laser System (Alcon
Surgical, Fort Worth, Texas). The epithelium was deb-
rided mechanically using either a 9.0 mm Amoils rotating
scrubber brush (Innovative Excimer Solutions, Toronto,
Canada) or with a dilute solution of 20 % alcohol for
approximately 30 s, depending on surgeon preference.
Prophylactic mitomycin-C (MMC) was used in 69
(57.5 %) retreatment cases, at either 0.01 % or 0.02 % con-
centration, and was applied to the stromal bed immedi-
ately following ablation for times ranging between 15 and
60 s, depending on surgeon preference.
The post-operative management of patients varied
little between surgeons and generally consisted of the
following treatment plan: topical moxifloxacin hydro-
chloride 0.5 % ophthalmic solution (Vigamox, Alcon
Laboratories, Fort Worth, Texas) four times daily for
one week; topical prednisolone acetate 1 % ophthalmic so-
lution (Pred Forte, Allergan Inc., Irvine, California) every
two hours for the first three days followed by four times
daily for the remainder of the first week followed by a six-
week taper; topical ketorolac tromethamine 0.4 % ophthal-
mic solution (Acular-LS, Allergan Inc., Irvine, California)
up to four times daily during the first 48 h as needed for
pain; and frequent lubrication with preservative-free artifi-
cial tears. A high oxygen transmissible soft contact lens
was placed on all eyes at the time of surgery and removed
after complete re-epithelialization, typically between four
and seven days. Postoperative data from regularly sched-
uled follow-up visits at one, three, and six months in-
cluded UDVA, manifest refraction, manifest refraction
spherical equivalent (MRSE), CDVA and complications,
including but not limited to corneal haze, dry eyes, and
steroid response ocular hypertension or glaucoma.
Visual outcomes were documented in terms of stand-
ard measures of efficacy, safety predictability and stabil-
ity. Efficacy was measured as the number (%) of eyes
achieving UDVA 20/20. Safety was measured in terms
of maintenance of CDVA within one line of preopera-
tive. Loss of more than one line CDVA from any cause
was considered a complication. Predictability was mea-
sured as the number (%) of eyes with MRSE within
±0.50 diopter (D) of emmetropia. Refractive stability
was measured as the number (%) of eyes with < 0.50 D
change in MRSE over a minimum six month follow-up
period. Safety index was calculated as the ratio of mean
postoperative CDVA over mean preoperative CDVA.
Efficacy index was measured by ratio of mean postoper-
ative UDVA over mean preoperative CDVA. Visual out-
comes were also graphically presented using a standard
format [15].
Results
Between January 2008 and April 2011, 78 patients (120
eyes) underwent WFO PRK retreatment for residual re-
fractive error at either WRAMC or MAMC. Table 1
summarizes the preoperative clinical and demographic
characteristics of these patients. The primary surgery
was surface ablation in 87 eyes (78 PRK, 9 LASEK) and
LASIK in 33 eyes. MMC was used in 69 (57.5 %) of the
retreatment cases at either 0.01 % or 0.02 % concentra-
tion for time periods ranging between 15 and 60 s. Sur-
face epithelium was debrided by the Amoils rotating
scrubber brush in 22 eyes and 20 % alcohol in 98 eyes.
There were no intraoperative complications. Follow-up
rate was 115 out of 120 eyes (95.8 %) at one month, 76
eyes (63.3 %) at three months, and 37 eyes (30.8 %) at
six months.
UDVA was ≥ 20/20 in 69 eyes (60.0 %) at one month,
54 eyes (71.1 %) at three months, and 27 eyes (73.0 %) at
six months follow-up. CDVA was maintained within ±1
line of pre-op in 113 of 115 eyes (98.3 %) at one month,
74 of 76 eyes (97.4 %) at three months, and 37 eyes
(100 %) at six months follow-up. MRSE was within
±0.50 D of emmetropia in 78 of 115 eyes (67.8 %) at one
month, 59 of 76 eyes (77.6 %) at three months, and 25
of 37 eyes (67.6 %) at six months follow-up. Based on
available data at one and six months postoperatively,
Table 1 Preoperative characteristics of patients who underwent
WFO PRK retreatments following previous laser refractive
surgery with PRK, LASEK, or LASIK between January 2008 and
April 2011 at Walter Reed Army Medical Center or Madigan
Army Medical Center
78 patients (120 eyes)
Age ± SD (years) 40.3 ± 8.3 (26–58)
Gender (% Female) 20 (25.6 %)
Sphere ± SD (D) −0.46 ± 1.08 (−3.00 to 2.00)
Cylinder ± SD (D) −0.67 ± 0.64 (0 to −2.50)
MRSE ± SD (D) −0.79 ± 0.94 (−3.00 to 1.88)
UDVA ± SD (logMAR) 0.31 ± 0.17 (0 to 1.00)
Snellen equivalent (20/x) 40 (20 to 200)
CDVA >20/20 (% of eyes) 100 %
Average Keratometry ± SD (D) 41.33 ± 1.91 (36.85 to 46.05)
Central Corneal Thickness ± SD (μm) 493 ± 46 (392 to 623)




MRSE= manifest refraction spherical equivalent, UDVA= uncorrected distance
visual acuity, CDVA= corrected distance visual acuity
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MRSE changed < 0.5 D between one and six month
follow-up in 21 of 35 eyes (60.0 %). The three month
postoperative visual outcomes are shown in Fig. 1. Of
the 76 eyes followed at three months postoperatively, 59
eyes (77.6 %) had UDVA within one line of their pre-
operative CDVA. Safety and efficacy indices progres-
sively improved over six months postoperatively
(Table 2). Dry eye was the most commonly reported
post-operative complication throughout the follow-up
period: 16 eyes (13.9 %) at one month, 16 eyes (21.1 %)
at three months, and 2 eyes (5.4 %) at six months. No
clinically significant corneal haze developed in any of the
Fig. 1 Three-month outcomes of wavefront-optimized PRK retreatment. a Uncorrected distance visual acuity. b Change in corrected distance
visual acuity. c Spherical equivalent attempted vs. achieved. d Spherical equivalent refractive accuracy. e Refractive astigmatism f Stability of
spherical equivalent refraction
Table 2 Safety and efficacy indices of wavefront-optimized PRK
retreatment




Safety index (post-op CDVA / pre-op CDVA)
Efficacy index (post-op UDVA / pre-op CDVA)
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eyes post-operatively. Corneal haze of grade 1+ or less
was noted in 13 eyes (11.3 %) at one month and 6 eyes
(7.9 %) at three months. All cases of corneal haze re-
solved without surgical intervention by six months. One
patient (2 eyes) had loss of two lines of CDVA at one
month follow-up, but subsequently regained them at
three month follow-up without intervention. A separate
patient (2 eyes) had no complications at one month
follow-up but had loss of two lines of CDVA at three
months, and subsequently was lost to further follow-up.
Table 3 summaries all complications over the six month
follow-up period.
Primary LASIK
Thirty-three eyes had LASIK as primary treatment.
The mean spherical equivalent before retreatment
was −0.70 ± 0.86 D (−1.75 to 1.25 D). UDVA was ≥
20/20 in 12 of 31 eyes (38.7 %) at one month, 18 of
24 eyes (75.0 %) at three months, and 5 of 6 eyes
(83.3 %) at six months follow-up. CDVA was main-
tained within ±1 line of pre-op in all eyes at one
month (31 eyes), three months (24 eyes), and six
months follow-up (6 eyes). MRSE was within ±0.50
D of emmetropia in 17 of 31 eyes (54.8 %) at one
month, 19 of 24 eyes (79.2 %) at three months, and
4 of 6 eyes (66.7 %) at six months follow-up. Based
on available data at one and six months postopera-
tively, MRSE changed < 0.5 D between one and six
month follow-up in 2 of 6 eyes (33.3 %).
Primary surface ablation
Eighty-seven eyes had surface ablation (78 PRK, 9
LASEK) as primary treatment. The mean spherical
equivalent before retreatment was −0.83 ± 0.97 D (−3.00
to 1.88 D). UDVA was ≥ 20/20 in 57 of 84 eyes (67.9 %)
at one month, 36 of 52 eyes (69.2 %) at three months,
and 22 of 31 eyes (71.0 %) at six months follow-up.
CDVA was maintained within ±1 line of pre-op in 82 of
84 eyes (97.6 %) at one month, 50 of 52 eyes (96.2 %) at
three months, and 31 eyes (100 %) at six months follow-
up. MRSE was within ±0.50 D of emmetropia in 61 of
84 eyes (72.6 %) at one month, 40 of 52 eyes (76.9 %) at
three months, and 21 of 31 eyes (67.7 %) at six months
follow-up. Based on available data at one and six months
postoperatively, MRSE changed < 0.5 D between one and
six month follow-up in 19 of 29 eyes (65.5 %).
Discussion
Wavefront technology has greatly improved our under-
standing of ocular aberration, and with its incorporation
into refractive surgery techniques, patients are experien-
cing better visual outcomes and greater satisfaction
when compared to conventional methods [2, 5]. In mul-
tiple studies, both WFG and WFO refractive surgeries
have been found to achieve essentially similar visual out-
comes [2, 4, 16]. The use of WFG technology for refract-
ive enhancement has also been shown to be safe and
effective [5]. However, the visual outcomes following
WFO retreatment have not yet been fully established.
From our review, retreatment using WFO PRK retreat-
ment following primary refractive surgery with PRK,
LASEK, or LASIK appears to be a safe, effective, and
predictable treatment method for correcting residual or
induced refractive error. Though our reduced long-term
follow-up rate limits our ability to comment on the
long-term stability of retreatment cases, our results indi-
cate that retreatments appear stable through to the six
month post-operative period. The results from our study
are consistent with results from the WFO retreatment
study by Randleman et al., although their study focused
primarily on the rate of retreatment and the factors in-
fluencing that rate, as opposed to visual outcomes from
the retreatment procedure [13]. Their study also briefly
noted WFO retreatment outcomes (UDVA), but did not
comment on the safety of this platform as a retreatment
method or on any post-retreatment complications [13].
In our study, there were no major adverse events follow-
ing WFO PRK retreatments. Dry eye was the most com-
mon complication seen in this study, but we were
unable to determine if the dry eye symptoms were worse
prior to retreatment or if these symptoms became
chronic given the limited follow-up duration. Our study
was limited primarily by low patient follow-up after
three months. This was most likely due to patients’
Table 3 Post-operative complications
Post-op complications 1 M (n = 115) 3 M (n = 76) 6 M (n = 37)
No. % No. % No. %
None 79 68.7 53 69.7 35 94.6
Dry eye 16 13.9 16 21.1 2 5.4
Corneal haze (trace) 10 8.7 4 5.3 0 0.0
Corneal haze (1+) 3 2.6 2 2.6 0 0.0
Corneal haze (2+ or >) 0 0.0 0 0.0 0 0.0
Corneal scar 0 0.0 0 0.0 0 0.0
Residual astigmatism 6 5.2 2 2.6 0 0.0
Induced astigmatism 6 5.2 1 1.3 0 0.0
Undercorrected 3 2.6 3 3.9 2 5.4
Overcorrected 11 9.6 1 1.3 1 2.7
Regression 0 0.0 0 0.0 0 0.0
Corneal abrasion 0 0.0 0 0.0 0 0.0
Delayed epithelial healing 0 0.0 0 0.0 0 0.0
Recurrent corneal erosion 0 0.0 0 0.0 0 0.0
Steroid responder 0 0.0 0 0.0 0 0.0
Corneal infiltrate 0 0.0 0 0.0 0 0.0
Other 0 0.0 0 0.0 0 0.0
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various active duty requirements, such as training exer-
cises and deployments, which precluded patients from
attending follow-up appointments. Ideally, more of our
patient population would return for regular re-visits and
for a longer follow-up duration to better assess refractive
outcomes; however, with all of our subjects being active
duty military personnel, a large portion of our patients
were moved to other military facilities, sent for pro-
longed training assignments, or deployed to Afghanistan
or Iraq for 12–15 month-long tours, during the follow-
up period. As a result, our ability to comment on the re-
fractive stability beyond the 6 month period is limited.
Further limitations to our study include surgical variabil-
ity between individual retreatment cases. Surgical vari-
ables that varied largely based on surgeon preference
included the method of epithelial debridement (brush or
alcohol), the decision to use MMC, and if used, the con-
centration and exposure time of MMC. The actual effect
of these surgical variables on visual outcomes has widely
been debated. The concentration of MMC used, the
stromal exposure time to MMC, and the correct situ-
ation to use MMC varies considerably between practices
and surgeons. A true consensus on the optimal use of
MMC had not yet been established in either primary or
retreatment cases.
The visual and refractive outcomes from this study are
comparable to the outcomes from other retreatment
studies. Jin and Merkley [10] compared visual outcomes
of conventional LASIK retreatments following either
primary WFG LASIK or primary conventional LASIK:
75.0 % of eyes in both of their study groups had UDVA >
20/20 following retreatment. In their WFG group,
91.0 % of eyes were within ±0.50 D of emmetropia, and
of their standard primary group, 87.0 % of eyes were
within ±0.50 D of emmetropia. In addition, they re-
ported that no eyes lost ≥ 2 lines of CDVA, which is also
true in our LASIK population subset. Within our study,
3.3 % of eyes (4 eyes of two patients) lost 2 lines of
CDVA; both patients were from our PRK subset group.
One of these patients (two eyes) improved and regained
CDVA at the next month of follow-up, and the second
patient maintained ±1 line CDVA until the last month
of follow-up. Our rate of 2.6 % is actually lower than
that reported in another Jin and Merkley [11] study
where outcomes of conventional and WFG myopic
LASIK retreatment were assessed. In their study, they
reported that 17 % of eyes in their WFG retreatment
group lost 2 lines of CDVA.
Many studies to date have shown very similar and often
excellent refractive outcomes following both primary and
retreatment cases utilizing either WFG or WFO plat-
forms. [1, 3, 5, 10, 16] Additionally, many studies have
shown that following WFG or WFO primary treatments,
there is a similar increase in the amount of induced higher
order aberrations [1, 17]. Given similar refractive out-
comes and induction of higher order aberrations between
the two platforms, albeit following primary refractive pro-
cedures, our experience was that the WFO platform was
best utilized for patients with higher refractive errors or
with a significant amount of astigmatism given the faster
laser ablation and more peripheral treatment profile. Most
retreatment cases, however, will not have markedly high
amounts of residual refractive error or astigmatism, so
either platform could be utilized by the surgeon.
During the study period, we performed 110 enhance-
ment procedures at WRAMC, which comprised 1.8 % of
the total number of refractive surgeries performed at this
center during the study period. Though our study did
not primarily focus on establishing a retreatment rate
during the study period, our experience with retreatment
cases appeared to be similar to others cited in the litera-
ture. Randleman et al. reported an overall retreatment
rate of 6.3 % following WFO PRK and LASIK. Kashani
et al. reported a retreatment rate of 3.1 % in their WFG
LASIK retreatment study; Netto and Wilson reported a
retreatment rate of 14 % in their standard LASIK
retreatment study.
Conclusion
While our study only provides a descriptive narrative
of WFO PRK retreatment outcomes, it demonstrates
potential outcomes and variables to be investigated in
future prospective studies. Our study also tentatively
establishes the safety of WFO PRK retreatments fol-
lowing any primary refractive surgery. Since the safety
of WFG retreatments has been established in several
studies, and WFO retreatment outcomes appear to
match those of WFG retreatments, our study allows
clinicians to have treatment options when faced with
patients needing retreatment. Our study also lays the
groundwork for a randomized controlled trial com-
paring the two platforms in retreatment cases.
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